Clinical Trials Directory

Trials / Sponsors / Sunesis Pharmaceuticals

Sunesis Pharmaceuticals

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
TerminatedSafety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma
Phase 1 / Phase 22017-04-28
CompletedStudy of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Acute Myeloid Leukemia
Phase 32010-12-17
CompletedStudy of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Leukemia, Acute Disease, Acute Myeloid Leukemia
Phase 22008-05-15
CompletedSafety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Acute Myeloid Leukemia
Phase 1 / Phase 22007-10-06
CompletedSafety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Advanced Solid Tumors
Phase 12007-08-01
CompletedStudy of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 12007-02-01
CompletedSafety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Epithelial Ovarian Cancer
Phase 22006-12-20
CompletedSafety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Carcinoma, Small Cell, Small Cell Lung Cancer
Phase 22006-02-01
CompletedSafety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Tumors
Phase 12006-01-01
CompletedSafety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
Phase 22005-12-27
CompletedSafety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malign
Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic
Phase 12005-11-14
CompletedSafety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Neoplasms
Phase 12004-10-01
CompletedInitial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Neoplasms
Phase 12004-06-01